ivocizumab
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 20, 2024 (NCT06683846)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Adrenal Gland Neoplasms · Phase 2
- Basal Cell Carcinoma · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Glioma · Phase 2
- Kidney Diseases · Phase 2
- Kidney Neoplasms · Phase 2
- Neoplasms · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neuroendocrine Tumors · Phase 2
- Paget Disease, Extramammary · Phase 2
- Penile Neoplasms · Phase 2
- Perivascular Epithelioid Cell Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 2
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06683846 | Phase 2 | Nov 20, 2024 | Fudan University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1